From DCAT Value Chain Insights (VCI)
The members of the GMP Committee of the International Pharmaceutical Excipients Council of the Americas (IPEC-Americas) recently finalized a position paper, “Conducting Accelerated Stability on Excipients," to address issues for IPEC-Americas members who are receiving requests from certain countries for accelerated stability (AS) data on excipient products that already have full long-term stability study data. IPEC-Americas said that several of its members received such requests in the first quarter of 2015.
IPEC-Americas said that these requests have come from regulatory agencies receiving product registrations in those countries or from excipient user companies exporting finished drug formulation into those countries. There have also been requests for ICH long-term, intermediate, and accelerated stability data and questions regarding differences between storage statements on safety data sheets and product stability documents.
The IPEC-Americas position paper establishes its position regarding the necessity of such studies or data on excipients that are already being sold commercially and have documented long-term stability studies. The paper does not address new excipients or excipients that are new chemical entities that do not have a history of storage and transporting.
The position paper may be found here.
Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT).
Learn more and sign up to receive a complimentary subscription